CD102 (ICAM-2) Monoclonal Antibody (CBR-IC2/2), eBioscience™, Invitrogen™

Description

• Description: BMS109 does not cross react with mouse
• Intercellular Adhesion Molecule-2 (ICAM-2) is a 60 kDa surface glycoprotein that promotes adhesion between immune cells and the vascular endothelium
• ICAM-2 is a member of the Ig-superfamily with two immunoglobulin-like extracellular domains
• ICAM-2 is much more closely related to the two N-terminal domains of ICAM-1 (34% identity) than either ICAM-1 or ICAM-2 is to other members of the Ig-superfamily, demonstrating the existence of a subfamily of Ig-like ligands that bind the same integrin receptor
• ICAM-2 is broadly distributed on hematopoietic cells
• On resting lymphocytes, the ICAM-2 expression is several-fold higher than that seen with ICAM-1, while monocytes express equivalent levels of ICAM-1 and ICAM-2
• In contrast to ICAM-1, neutrophils stain negative for ICAM-2
• Just little or no ICAM-2 staining can be demonstrated on other cell lines, the sole exception being resting vascular endothelial cells, which possess high levels of ICAM-2, and small clusters of cells in lymphoid tissue germinal centres
• ICAM-2 expression is unaffected by a variety of inflammatory cytokines
• Applications Tested: ELISA, Flow Cytometry, Functional Studies (Blocking), Immunohistochemistry
• Purity: >95%
• ICAM-2 is a member of the intercellular adhesion molecule (ICAM) family
• All ICAM proteins are type I transmembrane glycoproteins, contain 2-9 immunoglobulin-like C2-type domains, and bind to the leukocyte adhesion LFA-1 protein
• ICAM-2 may play a role in lymphocyte recirculation by blocking LFA-1-dependent cell adhesion
• It mediates adhesive interactions important for antigen-specific immune response, NK-cell mediated clearance, lymphocyte recirculation, and other cellular interactions important for immune response and surveillance
• Several transcript variants encoding the same protein have been found for this gene
• Diseases associated with ICAM2 include Colon Carcinoma In Situ.